innovation for industry
Diabeloop obtained French national health
insurance approval for its DBLG1 closed-loop automated insulin therapy device (DBLG1)
Now the Grenoble start-up and long-time CEA-Leti partner is training hospital staff so that they can offer the DBLG1 to their diabetic patients. Hospitals in the Île-de-France and Auvergne-Rhône-Alpes regions recently set their first patients up with the device, which will be rolled out gradually throughout France in 2022. And Diabeloop is also expanding internationally.
The company signed a partnership agreement with leading Japanese medical equipment manufacturer Terumo in mid-November. The partners will integrate Terumo's patch pump into Diabeloop's system so that the Japanese company can sell it in Europe.
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.